Journal Watch · Clinical Pharmacology & Therapeutics · 2026

Digital Transformation of Medicines Regulation in Africa-Perspectives from a Stakeholder Convening.

This paper summarizes discussions from a convening to identify priorities for digitization and digital transformation of African medicines regulation.

Reyneke C, Semete-Makokotlela B, Singh V et al.Clinical Pharmacology & Therapeutics3 min readPharma relevance 50/100

DOI: 10.1002/cpt.70351PMID: 42231040Study type: review / perspective

TL;DR

This paper summarizes discussions from a convening to identify priorities for digitization and digital transformation of African medicines regulation.

Key findings

  • The South African Health Products Regulatory Authority (SAHPRA) is implementing AI within a structured digitization strategy, including AI-assisted dossier screening and automated GMP review to address backlogs and workflow inefficiencies.
  • The Medicines Control Authority of Zimbabwe (MCAZ) deploys AI-driven dossier screening through its in-house digital systems, while Kenya's Pharmacy and Poisons Board has proposed a risk-based framework for regulating AI-enabled medical devices.
  • At the continental level, the African Medicines Agency and AUDA-NEPAD aim to harmonize digital transformation and responsible AI adoption through reliance and cross-border data sharing.
  • This paper summarizes discussions from a convening to identify priorities for digitization and digital transformation of African medicines regulation.

What they did

The agency emphasizes credibility and validation through a risk-based framework that evaluates AI models according to their influence on regulatory decisions and potential consequences of error. In Europe, the EMA pursues system-level digital transformation, embedding AI within a broader data and analytics strategy emphasizing interoperability, data structuring, automation, and governance supported by legislation. African national regulatory authorities are advancing AI through pragmatic pilot initiatives.

Full abstract (original)

Background: Regulatory authorities worldwide are developing strategies to integrate artificial intelligence (AI) into the lifecycle of health products, technologies, and medicines. While regulators share goals of improving efficiency, strengthening decision-making, and protecting public health, their approaches differ according to institutional structures, capacity, maturity, and regional priorities. In the United States, the FDA adopts a model-focused approach, treating AI primarily as a regulatory science tool to strengthen analytical components of decisions such as patient selection, biomarker substitution, and predictive modeling.

What they did: The agency emphasizes credibility and validation through a risk-based framework that evaluates AI models according to their influence on regulatory decisions and potential consequences of error. In Europe, the EMA pursues system-level digital transformation, embedding AI within a broader data and analytics strategy emphasizing interoperability, data structuring, automation, and governance supported by legislation. African national regulatory authorities are advancing AI through pragmatic pilot initiatives.

Results & conclusions: The South African Health Products Regulatory Authority (SAHPRA) is implementing AI within a structured digitization strategy, including AI-assisted dossier screening and automated GMP review to address backlogs and workflow inefficiencies. The Medicines Control Authority of Zimbabwe (MCAZ) deploys AI-driven dossier screening through its in-house digital systems, while Kenya's Pharmacy and Poisons Board has proposed a risk-based framework for regulating AI-enabled medical devices. At the continental level, the African Medicines Agency and AUDA-NEPAD aim to harmonize digital transformation and responsible AI adoption through reliance and cross-border data sharing. This paper summarizes discussions from a convening to identify priorities for digitization and digital transformation of African medicines regulation.

Abstract © the authors / Clinical Pharmacology & Therapeutics (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1002/cpt.70351 · PubMed 42231040.

Why it matters for pharma & biotech

  • Directly relevant to teams in AI in drug discovery / diagnostics — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: AI in drug discovery / diagnostics

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Clinical Pharmacology & Therapeutics study find?

This paper summarizes discussions from a convening to identify priorities for digitization and digital transformation of African medicines regulation.

What type of study is this?

It is a review / perspective, published in Clinical Pharmacology & Therapeutics in 2026. The agency emphasizes credibility and validation through a risk-based framework that evaluates AI models according to their influence on regulatory decisions and potential consequences of error.

Where can I read the original paper?

The original is at the publisher via DOI 10.1002/cpt.70351. PubMed ID: 42231040. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Reyneke C, Semete-Makokotlela B, Singh V et al.. Digital Transformation of Medicines Regulation in Africa-Perspectives from a Stakeholder Convening.. Clinical Pharmacology & Therapeutics (2026). DOI: 10.1002/cpt.70351.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/digital-transformation-of-medicines-regulation-in-africa-perspectives-fr-t70351/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides